Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:33:56 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:RARE from 2023-05-07 to 2024-05-06 - 56 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:00U:RARENews ReleaseUltragenyx Reports First Quarter 2024 Financial Results and Corporate Update
2024-04-30 16:00U:RARENews ReleaseUltragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
2024-04-30 08:00U:RARENews ReleaseUltragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
2024-04-25 16:30U:RARENews ReleaseUltragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
2024-04-19 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-04-15 07:00U:RARENews ReleaseUltragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
2024-04-12 16:23U:RARENews ReleaseUltragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
2024-04-12 08:00U:RARENews ReleaseUltragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
2024-03-22 16:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-02-27 16:30U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in March
2024-02-23 16:05U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-02-15 16:01U:RARENews ReleaseUltragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2024-02-08 16:00U:RARENews ReleaseUltragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
2024-02-06 08:00U:RARENews ReleaseUltragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
2024-02-05 16:05U:RARENews ReleaseUltragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
2024-01-25 16:05U:RARENews ReleaseUltragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
2024-01-19 16:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 07:00U:RARENews ReleaseMereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
2024-01-07 11:00U:RARENews ReleaseUltragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
2024-01-04 08:00U:RARENews ReleaseUltragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza ‚ ® ¢ – ¼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2024-01-03 08:00U:RARENews ReleaseUltragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
2024-01-02 16:05U:RARENews ReleaseUltragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 08:00U:RARENews ReleaseUltragenyx Receives European Commission Decision for Evkeeza ‚ ® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
2023-11-20 16:30U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in November
2023-11-17 16:30U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 17:00U:RARENews ReleaseUltragenyx to Participate in the Jefferies London Healthcare Conference
2023-11-02 16:05U:RARENews ReleaseUltragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
2023-10-26 16:05U:RARENews ReleaseUltragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
2023-10-23 16:01U:RARENews ReleaseUltragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-10-20 16:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-10-18 21:17U:RARENews ReleaseUltragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2023-10-17 16:02U:RARENews ReleaseUltragenyx Announces Proposed Public Offering of Common Stock
2023-10-16 08:00U:RARENews ReleaseUltragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
2023-10-14 16:30U:RARENews ReleaseUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
2023-10-12 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-10-09 08:00U:RARENews ReleaseUltragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
2023-10-05 08:00U:RARENews ReleaseUltragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023
2023-09-25 17:13U:RARENews ReleaseUltragenyx Launches Evkeeza ‚ ® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
2023-09-20 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-08-31 09:00U:RARENews ReleaseUltragenyx to Participate at Investor Conferences in September
2023-08-18 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 16:00U:RARENews ReleaseUltragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
2023-07-31 08:00U:RARENews ReleaseUltragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
2023-07-27 17:00U:RARENews ReleaseUltragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
2023-07-18 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-07-12 08:00U:RARENews ReleaseUltragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
2023-07-06 08:00U:RARENews ReleaseUltragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
2023-06-21 08:00U:RARENews ReleaseUltragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
2023-06-20 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 17:00U:RARENews ReleaseUltragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-05 16:01U:RARENews ReleaseUltragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
2023-05-19 08:30U:RARENews ReleaseUltragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
2023-05-18 17:00U:RARENews ReleaseUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-05-17 08:00U:RARENews ReleaseUltragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
2023-05-08 16:02U:RARENews ReleaseUltragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting